T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

A research team has validated a way to outfox tumors. They engineered T-cells, essential players in the body's own immune system, to strip tumors of their self-preservation skill and were able to hold Hodgkin lymphoma at bay in patients with relapsed disease for more than four years.